← United States · Coverage record
US · SEC FORM 4
Mind Medicine (MindMed) Inc.
MNMD · Nasdaq · CIK 0001813814 · Healthcare
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
35 Form 4 transaction lines observed in the same window
11 sales · 24 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
Showing the six most active owners; 1 additional owner(s) remain in Form 4 evidence.
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2024-12-05 · GRYSKA DAVID W.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
The FINRA report lists no short interest for this ticker.
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2024-12-05 | GRYSKA DAVID W | Purchase (P) | Common Shares | 2,500 | USD 7.17 | USD 17,925 | SEC filing ↗ |
| 2024-08-23 | GRYSKA DAVID W | Purchase (P) | Common Shares | 3,500 | USD 5.98 | USD 20,930 | SEC filing ↗ |
| 2024-08-20 | Barrow Robert | Purchase (P) | Common Shares | 500 | USD 6.12 | USD 3,060 | SEC filing ↗ |
| 2024-08-19 | Barrow Robert | Purchase (P) | Common Shares | 500 | USD 6.31 | USD 3,155 | SEC filing ↗ |
Form 4 evidence
46 transaction lines in the latest 365-day window; 160 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-09-25 | Wiley Matthew T. | Sale (S) | Common Shares | 3,097 | USD 36.57 | USD 113,257 | SEC filing ↗ |
| 2026-09-25 | Sullivan Mark | Sale (S) | Common Shares | 14,051 | USD 36.57 | USD 513,845 | SEC filing ↗ |
| 2026-09-25 | Roberts Brandi | Sale (S) | Common Shares | 3,377 | USD 36.57 | USD 123,497 | SEC filing ↗ |
Show recent Form 4 evidence (30 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-09-25 | Wiley Matthew T. | Sale (S) | Common Shares | 3,097 | USD 36.57 | USD 113,257 | SEC filing ↗ |
| 2026-09-25 | Sullivan Mark | Sale (S) | Common Shares | 14,051 | USD 36.57 | USD 513,845 | SEC filing ↗ |
| 2026-09-25 | Roberts Brandi | Sale (S) | Common Shares | 3,377 | USD 36.57 | USD 123,497 | SEC filing ↗ |
| 2026-09-25 | Karlin Daniel | Sale (S) | Common Shares | 10,853 | USD 36.57 | USD 396,894 | SEC filing ↗ |
| 2026-09-25 | Barrow Robert | Sale (S) | Common Shares | 31,550 | USD 36.57 | USD 1,153,784 | SEC filing ↗ |
| 2026-09-18 | Vallone Carol A | Option exercise / conversion (M) | Common Shares | 1,086 | USD 35.52 | USD 38,575 | SEC filing ↗ |
| 2026-09-18 | Krebs Andreas | Option exercise / conversion (M) | Common Shares | 1,629 | USD 35.52 | USD 57,862 | SEC filing ↗ |
| 2026-09-14 | Wiley Matthew T. | Award / grant (A) | Common Shares | 125,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-09-14 | Sullivan Mark | Award / grant (A) | Common Shares | 125,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-09-14 | Roberts Brandi | Award / grant (A) | Common Shares | 125,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-09-14 | Karlin Daniel | Award / grant (A) | Common Shares | 200,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-09-14 | Barrow Robert | Award / grant (A) | Common Shares | 750,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-09-03 | Barrow Robert | Sale (S) | Common Shares | 19,023 | USD 37.94 | USD 721,733 | SEC filing ↗ |
| 2026-09-02 | Barrow Robert | Award / grant (A) | Common Shares | 40,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-08-12 | Wiley Matthew T. | Award / grant (A) | Common Shares | 62,500 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-08-12 | Sullivan Mark | Award / grant (A) | Common Shares | 62,500 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-08-12 | Roberts Brandi | Award / grant (A) | Common Shares | 62,500 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-08-12 | Karlin Daniel | Award / grant (A) | Common Shares | 100,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-08-12 | Barrow Robert | Award / grant (A) | Common Shares | 375,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-25 | Wiley Matthew T. | Sale (S) | Common Shares | 2,867 | USD 45.03 | USD 129,101 | SEC filing ↗ |
| 2026-06-25 | Sullivan Mark | Sale (S) | Common Shares | 13,008 | USD 45.03 | USD 585,750 | SEC filing ↗ |
| 2026-06-25 | Roberts Brandi | Sale (S) | Common Shares | 3,013 | USD 45.03 | USD 135,675 | SEC filing ↗ |
| 2026-06-25 | Karlin Daniel | Sale (S) | Common Shares | 10,035 | USD 45.03 | USD 451,876 | SEC filing ↗ |
| 2026-06-25 | Barrow Robert | Sale (S) | Common Shares | 29,208 | USD 45.03 | USD 1,315,236 | SEC filing ↗ |
| 2026-06-22 | Wiley Matthew T. | Award / grant (A) | Common Shares | 62,500 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-22 | Sullivan Mark | Award / grant (A) | Common Shares | 62,500 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-22 | Roberts Brandi | Award / grant (A) | Common Shares | 62,500 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-22 | Karlin Daniel | Award / grant (A) | Common Shares | 100,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-22 | Barrow Robert | Award / grant (A) | Common Shares | 375,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-11 | Vallone Carol A | Award / grant (A) | Common Shares | 4,666 | USD 0.00 | USD 0 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | MNMD |
| CIK | 0001813814 |
| Sector | Healthcare |
| Industry | — Yahoo Finance |
| SEC SIC | 2833 Medicinal Chemicals & Botanical Products |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 160 transaction lines from 2022-01-15 to 2026-09-25 4 P purchase lines · 82 S sale lines · 74 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.